rs2917726

Variant summary

Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1

The NM_152743.4(BRAT1):​c.1923G>A​(p.Ala641Ala) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0586 in 1,597,516 control chromosomes in the GnomAD database, including 4,204 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.048 ( 349 hom., cov: 34)
Exomes 𝑓: 0.060 ( 3855 hom. )

Consequence

BRAT1
NM_152743.4 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:4

Conservation

PhyloP100: -0.460

Publications

6 publications found
Variant links:
Genes affected
BRAT1 (HGNC:21701): (BRCA1 associated ATM activator 1) The protein encoded by this ubiquitously expressed gene interacts with the tumor suppressing BRCA1 (breast cancer 1) protein and and the ATM (ataxia telangiectasia mutated) protein. ATM is thought to be a master controller of cell cycle checkpoint signalling pathways that are required for cellular responses to DNA damage such as double-strand breaks that are induced by ionizing radiation and complexes with BRCA1 in the multi-protein complex BASC (BRAC1-associated genome surveillance complex). The protein encoded by this gene is thought to play a role in the DNA damage pathway regulated by BRCA1 and ATM. [provided by RefSeq, Mar 2012]
BRAT1 Gene-Disease associations (from GenCC):
  • neonatal-onset encephalopathy with rigidity and seizures
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Ambry Genetics, Orphanet, ClinGen, G2P, Labcorp Genetics (formerly Invitae)
  • neurodevelopmental disorder with cerebellar atrophy and with or without seizures
    Inheritance: AR Classification: DEFINITIVE Submitted by: ClinGen, Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.7).
BP6
Variant 7-2538612-C-T is Benign according to our data. Variant chr7-2538612-C-T is described in ClinVar as Benign. ClinVar VariationId is 585488.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=-0.46 with no splicing effect.
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.237 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
BRAT1NM_152743.4 linkc.1923G>A p.Ala641Ala synonymous_variant Exon 14 of 14 ENST00000340611.9 NP_689956.2 Q6PJG6-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
BRAT1ENST00000340611.9 linkc.1923G>A p.Ala641Ala synonymous_variant Exon 14 of 14 1 NM_152743.4 ENSP00000339637.4 Q6PJG6-1

Frequencies

GnomAD3 genomes
AF:
0.0484
AC:
7365
AN:
152154
Hom.:
348
Cov.:
34
show subpopulations
Gnomad AFR
AF:
0.0125
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.0721
Gnomad ASJ
AF:
0.0657
Gnomad EAS
AF:
0.247
Gnomad SAS
AF:
0.0624
Gnomad FIN
AF:
0.0354
Gnomad MID
AF:
0.0701
Gnomad NFE
AF:
0.0505
Gnomad OTH
AF:
0.0497
GnomAD2 exomes
AF:
0.0680
AC:
15287
AN:
224900
AF XY:
0.0660
show subpopulations
Gnomad AFR exome
AF:
0.0104
Gnomad AMR exome
AF:
0.0783
Gnomad ASJ exome
AF:
0.0721
Gnomad EAS exome
AF:
0.248
Gnomad FIN exome
AF:
0.0307
Gnomad NFE exome
AF:
0.0499
Gnomad OTH exome
AF:
0.0546
GnomAD4 exome
AF:
0.0596
AC:
86198
AN:
1445244
Hom.:
3855
Cov.:
83
AF XY:
0.0593
AC XY:
42657
AN XY:
719450
show subpopulations
African (AFR)
AF:
0.00936
AC:
313
AN:
33436
American (AMR)
AF:
0.0782
AC:
3479
AN:
44508
Ashkenazi Jewish (ASJ)
AF:
0.0726
AC:
1893
AN:
26058
East Asian (EAS)
AF:
0.276
AC:
10919
AN:
39604
South Asian (SAS)
AF:
0.0573
AC:
4929
AN:
86090
European-Finnish (FIN)
AF:
0.0310
AC:
1203
AN:
38866
Middle Eastern (MID)
AF:
0.0664
AC:
382
AN:
5756
European-Non Finnish (NFE)
AF:
0.0533
AC:
59227
AN:
1110848
Other (OTH)
AF:
0.0641
AC:
3853
AN:
60078
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.496
Heterozygous variant carriers
0
5480
10960
16439
21919
27399
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
2404
4808
7212
9616
12020
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0484
AC:
7374
AN:
152272
Hom.:
349
Cov.:
34
AF XY:
0.0510
AC XY:
3799
AN XY:
74456
show subpopulations
African (AFR)
AF:
0.0124
AC:
517
AN:
41570
American (AMR)
AF:
0.0724
AC:
1108
AN:
15310
Ashkenazi Jewish (ASJ)
AF:
0.0657
AC:
228
AN:
3470
East Asian (EAS)
AF:
0.248
AC:
1280
AN:
5160
South Asian (SAS)
AF:
0.0626
AC:
302
AN:
4822
European-Finnish (FIN)
AF:
0.0354
AC:
376
AN:
10622
Middle Eastern (MID)
AF:
0.0753
AC:
22
AN:
292
European-Non Finnish (NFE)
AF:
0.0505
AC:
3435
AN:
67998
Other (OTH)
AF:
0.0501
AC:
106
AN:
2116
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
362
723
1085
1446
1808
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
84
168
252
336
420
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0500
Hom.:
44
Bravo
AF:
0.0504
Asia WGS
AF:
0.146
AC:
506
AN:
3478
EpiCase
AF:
0.0508
EpiControl
AF:
0.0489

ClinVar

Significance: Benign
Submissions summary: Benign:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:2
Jul 15, 2018
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Apr 20, 2017
Athena Diagnostics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not specified Benign:1
Jul 15, 2024
Unidad de Genómica Garrahan, Hospital de Pediatría Garrahan
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is classified as Benign based on local population frequency. This variant was detected in 23% of patients studied in a panel designed for Epileptic and Developmental Encephalopathy and Progressive Myoclonus Epilepsy. Number of patients: 21. Only high quality variants are reported. -

Neonatal-onset encephalopathy with rigidity and seizures Benign:1
Feb 04, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.70
CADD
Benign
5.0
DANN
Benign
0.68
PhyloP100
-0.46
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs2917726; hg19: chr7-2578246; COSMIC: COSV61394030; COSMIC: COSV61394030; API